RPCONE
MCRB icon

Retirement Planning Company of New England’s Seres Therapeutics MCRB Stock Holding History

Retirement Planning Company of New England’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-48
Closed -$7K – 606
2021
Q4 		$7K Buy
+48
New +$7.63K ﹤0.01% 708

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Retirement Planning Company of New England's MCRB Position: Q1 2022 in Review

Retirement Planning Company of New England sold out of Seres Therapeutics (MCRB) in Q1 2022, closing a stake of 48 shares — an estimated $7K sold.

Retirement Planning Company of New England first reported a position in MCRB in Q4 2021 and held it in 1 quarter. The position peaked at $7K in Q4 2021. 131 funds tracked by Wall St. Rank hold MCRB as of Q1 2022.

  • Retirement Planning Company of New England reported no remaining Seres Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Retirement Planning Company of New England sold 48 Seres Therapeutics shares in Q1 2022, an estimated $7K.
  • Retirement Planning Company of New England first reported a position in Seres Therapeutics in Q4 2021 and held it in 1 quarter.
  • Retirement Planning Company of New England's Seres Therapeutics position peaked at $7K in Q4 2021.
  • 131 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2022.

Based on Retirement Planning Company of New England's 13F filing for Q1 2022, filed 6 May 2022.